Mission-driven early-stage venture firm founded by Steve Jurvetson and Maryanna Saenko, investing in frontier technologies and new industries.
Founded 2018
Type Venture capital 5 Future Ventures IV, L.P. 2025-05-06 2025-05-06 — SEC filed/signed 2025-05-06: USD 200000000 offered/sold, zero remaining, 123 investors; first sale 2025-05-02. Latest-known numbered flagship in sources checked. Regulatory fully sold offering distinct from final-close commitments.
Future Ventures AI, LLC 2024-05-30 2024-05-30 — SEC signed 2024-05-30: USD 168873585 offered/sold, zero remaining, 68 investors; first sale 2024-05-09. Separate vehicle managed by Future Ventures GP III, LLC. Regulatory fully sold offering, not audited AUM or independently verified final-close commitments.
Future Ventures Fund III 2023-04-12 2023-04-12 $200M USD 200m closed; April 12, 2023 dated coverage. Distinct from Final Frontier Fund III.
Future Ventures Fund II 2021-01-12 2021-01-12 $200M USD 200m closed; January 12, 2021 dated coverage; separate vintage, not AUM.
Future Ventures Fund I 2019-02-15 2019-02-15 $200M USD 200m, single close; public launch dated 2019-02-15 by contemporaneous TechCrunch. Firm established 2018, fund launch 2019.
SHOW MORE
$7M 2026-08-31 Molten Salt Solutions Dolby Family Ventures , Future Ventures $125M 2025-12-17 Mythic DCVC , Future Ventures , Rouz Jazayeri , Matt Ocko $10M 2025-01-21 NeuroBionics Future Ventures $40M 2022-05-10 Osmind Future Ventures , Candace Richardson , Katherine Boyle $55M 2022-01-19 64xBio Fifty Years , Future Ventures $20M 2022-01-18 Faeth Khosla Ventures , Future Ventures , S2G Ventures , Digitalis Ventures , KdT Ventures , AgFunder , Cantos Ventures , Unshackled Ventures $40M 2020-01-07 Deep Genomics Future Ventures , Vinod Khosla $115M 2019-06-27 Commonwealth Fusion Systems Breakthrough Energy Ventures , Khosla Ventures , Vinod Khosla , Future Ventures , Lowercase Capital , Moore Strategic Ventures , Safar Partners , Schooner Capital , Starlight Ventures , Eni , The Engine , Engine Ventures , Future Fund $— Unknown date Zyphra Future Ventures $— Unknown date zoox Future Ventures $— Unknown date ZaiNar Future Ventures $— Unknown date YourChoice Therapeutics Future Ventures $— Unknown date xtime Future Ventures $— Unknown date Xona 2025-11-05- Future Ventures $— Unknown date XAI 2024-0513- Future Ventures $— Unknown date woola must vaike Future Ventures $— Unknown date Vironexis 2024-0903- Future Ventures $— Unknown date Verdant Robotics Future Ventures $— Unknown date UPSIDE Foods Future Ventures $— Unknown date UnConventional 2025-1118-- Future Ventures $— Unknown date tradex Future Ventures $— Unknown date The Boring Company Future Ventures $— Unknown date tesla Future Ventures $— Unknown date sutro Future Ventures $— Unknown date Subcritical Future Ventures $— Unknown date Stardust Future Ventures $— Unknown date Sphere Future Ventures $— Unknown date SpaceX Future Ventures $— Unknown date skype Future Ventures $— Unknown date Shennon Bio Future Ventures $— Unknown date Sensei Biotherapeutics Future Ventures $— Unknown date ScieNFT Future Ventures $— Unknown date Robust AI Future Ventures $— Unknown date Red Metals Future Ventures $— Unknown date Realta 2025-08-25 17.00.42-- Future Ventures $— Unknown date Pumpkinseed Future Ventures $— Unknown date Prellis Bio 2024-0906- Future Ventures $— Unknown date planetIPO Future Ventures $— Unknown date OutcomeMD Future Ventures $— Unknown date OpenTrons Future Ventures $— Unknown date nervana Future Ventures $— Unknown date Neophotonics Future Ventures $— Unknown date MosaicML Future Ventures $— Unknown date Moonwalk ---2 Future Ventures $— Unknown date Mojo Vision Future Ventures $— Unknown date Modulate Future Ventures $— Unknown date Latent AI Future Ventures $— Unknown date Lace Lithography Future Ventures $— Unknown date Kind Biotechnology Future Ventures $— Unknown date kana Future Ventures $— Unknown date interwoven Future Ventures $— Unknown date Hum Capital Future Ventures $— Unknown date hotmail Future Ventures $— Unknown date Hephae Energy Technology Future Ventures $— Unknown date GreenLight Biosciences Future Ventures $— Unknown date Glass Imaging Future Ventures $— Unknown date Gaussion Future Ventures $— Unknown date Gameto Future Ventures $— Unknown date Faeth Therapeutics Future Ventures $— Unknown date everspin Future Ventures $— Unknown date Enriched Ag Future Ventures $— Unknown date Earthshot Labs Future Ventures $— Unknown date dwaveIPO Future Ventures $— Unknown date Decibel-- Future Ventures $— Unknown date cyras Future Ventures $— Unknown date culture pink Future Ventures $— Unknown date Copernic Catalysts Future Ventures $— Unknown date CFS- Future Ventures $— Unknown date Centivax Future Ventures $— Unknown date Cambrian Bio Future Ventures $— Unknown date BMC Ingredients Future Ventures $— Unknown date BeeFlow Future Ventures $— Unknown date atai Life Sciences Future Ventures $— Unknown date Astonishing Labs Future Ventures $— Unknown date Amplifier Therapeutics Future Ventures $— Unknown date Ambrosia Energy Future Ventures $— Unknown date Alice Technologies Future Ventures
SHOW MORE
team@apexlogos.ai · 2 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund sizes, vintages and status
Amounts are fund capital, not investee rounds or individual check sizes.
| Vehicle | Amount and status | Date/evidence | Caveat |
| --- | --- | --- | --- |
| Fund I | USD 200M; firm says a single close | Official [news page](https://future.ventures/news ), undated launch item; launch independently dated 2019-02-15 by [TechCrunch](https://techcrunch.com/2019/02/15/steve-jurvetson-tells-all-about-his-new-200-million-fund-his-new-partner-his-new-shopping-list-and-more/ ) | The firm's establishment in 2018 differs from the 2019 public fund launch. |
| Fund II / Future Ventures 2 | USD 200M; closed | Official [news page](https://future.ventures/news ), undated; dated 2021-01-12 by [TechCrunch](https://techcrunch.com/2021/01/12/a-deep-dive-on-steve-jurvetson-and-maryanna-saenkos-200-million-new-fund/ ) | A separate vintage, not AUM. |
| Fund III | USD 200M; closed | Official [news page](https://future.ventures/news ), undated; April 2023 dated coverage: [TechCrunch](https://techcrunch.com/2023/04/12/talking-with-future-ventures-about-its-new-fund-ai-hype-and-siri-sucking/ ) (2023-04-12) | Do not confuse flagship III with separately named Final Frontier Fund III. |
| Future Ventures AI, LLC | USD **168,873,585** offering and amount sold, USD 0 remaining; 68 investors | [SEC Form D](https://www.sec.gov/Archives/edgar/data/2021509/000202150924000001/xslFormDX01/primary_doc.xml ), signed 2024-05-30; first sale 2024-05-09 | Separate vehicle managed by Future Ventures GP III, LLC; filing does not establish a broad new flagship mandate. Rounded USD 169M reports are consistent with the exact filing figure. |
| Future Ventures IV, L.P. | USD **200,000,000** offering and amount sold, USD 0 remaining; 123 investors | [SEC Form D](https://www.sec.gov/Archives/edgar/data/2065683/000206235125000001/xslFormDX01/primary_doc.xml ), signed/filed 2025-05-06; first sale 2025-05-02; [filing index](https://www.sec.gov/Archives/edgar/data/2065683/0002062351-25-000001-index.htm ) | Fully sold offering as disclosed by issuer; SEC filing is not an SEC audit of accuracy. |
The [Final Frontier Fund III SEC filing](https://www.sec.gov/Archives/edgar/data/1930168/000193016822000002/xslFormDX08/primary_doc.xml ) (2022-06-03) confirms another similarly numbered vehicle exists. It is not treated as flagship Fund III or combined with the amounts above.
No current independently verified AUM or unallocated investment budget was established. Do not simply add historical fund commitments and call the result current AUM: side funds, SPVs, overlapping vehicles, distributions and valuations can affect that number. Searches for Fund V and 2026 closes found no primary-source-confirmed newer flagship. [Private Equity International's profile](https://www.privateequityinternational.com/institution-profiles/future-ventures.html ) (undated) lists “Magicus Ventures,” September 2026, under this manager, but conceals size and also contains generic placeholder language. **This is an unresolved potentially misassigned lead**, not a verified new Future Ventures fund.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Future Ventures Fund I | USD 200000000 | 2019-02-15 |
| Future Ventures Fund II | USD 200000000 | 2021-01-12 |
| Future Ventures Fund III | USD 200000000 | 2023-04-12 |
| Future Ventures AI, LLC | Undisclosed / unverified | 2024-05-30 |
| Future Ventures IV, L.P. | Undisclosed / unverified | 2025-05-06 | SHOW MORE
team@apexlogos.ai · 3 hours ago
Historical portfolio evidence associates Future Ventures with Neuralink: https://future.ventures/investments/ . Original research dated 2026-09-14; exact transaction, amount and date not established. Preserved as relationship evidence, not an identified funding round. Funding cleanup reviewed 2026-10-06. SHOW MORE
team@apexlogos.ai · 3 hours ago
Match research 2026-10-06 / FutureVentures / sha256:acaba7cb36a59f9e04e637ba693ac1e1a5357893d00950571a6b9fc5831f33d6 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **64x Bio** | Cell-line genome engineering, high-throughput screening and computational selection to improve viral-vector manufacturing for gene therapies | Significant participant in **USD 55M Series A**, **2022-01-19**, led by Lifeforce Capital. [Official release](https://64xbio.com/articles/64x-bio-raises-55-million-series-a-financing-to-advance-cell-line-engineering-platform-for-gene-therapy-manufacturing ). Confirms an otherwise undated Adex portfolio import. |
| **Faeth Therapeutics** | Cancer-metabolism research and machine-learning-assisted precision nutrition paired with cancer therapies | **Co-led USD 20M seed with Khosla Ventures**, **2022-01-18**. [Company release via Business Wire](https://www.businesswire.com/news/home/20220118005022/en/Faeth-Therapeutics-Raises-%2420M-to-Advance-Precision-Nutrition-Platform-as-A-New-Modality-in-Cancer-Treatment ). This is scientifically grounded therapeutic R&D; it is not a neural-interface company. |
| **Mythic** | Analog compute-in-memory semiconductor architecture for neural-network inference; specialized chips rather than ordinary application SaaS | Participant in **USD 125M financing led by DCVC**, **2025-12-17**. [Official release](https://www.mythic.ai/newsroom/blog-post-title-three-y3peb-4lwnz-5pkhf-baylp ). The announcement explicitly names Future Ventures. It calls the event a funding round without a series designation; use that wording unless independently verified. Jurvetson's earlier first investment predates this firm's history and must be kept separate. Claimed energy-efficiency improvements are company claims. |
| **Molten Salt Solutions** | Lithium-isotope enrichment process for fusion and advanced fission supply chains, progressing from laboratory work to pilot production | Participant in closed **USD 7M seed**, **2026-08-31**, led by Dolby Family Ventures. [Company release via PR Newswire](https://www.prnewswire.com/news-releases/molten-salt-solutions-raises-7-million-to-scale-lithium-enrichment-for-advanced-nuclear-energy-302863208.html ). Recent direct attribution confirms continued frontier-hardware investing. |
The [firm news page](https://future.ventures/news ) additionally identifies Robust.AI as its first Fund III investment, and confirms Moonwalk, Amplifier Therapeutics, Beeflow, Better Meat and Verdant Robotics portfolio associations. These support further review but are not substituted for round-specific primary verification here. Partner-history examples such as Tesla, SpaceX, Planet, D-Wave and Nervana require the original financing investor/fund to be identified before importing them as Future Ventures transactions.
## Previous neurotech investments
### NeuroBionics — direct neurotechnology, strong firm attribution
NeuroBionics develops flexible implanted bioelectronic fibers for minimally invasive **endovascular neuromodulation**, reaching neural structures through blood vessels. This directly interfaces with/modulates neural tissue, rather than merely supplying mental-health software.
- **2025-01-21:** official company announcement of a closed **USD 5M seed**, led by Dolby Family Ventures, explicitly lists **Future Ventures** as a participant. [Official announcement](https://neurobionics.io/press/neurobionics-seed-press-release/ ).
- **2025-12-16:** official company announcement says the **second close was led by Future Ventures**, and the combined seed financing brought total funding to **USD 10M**. [Official announcement](https://neurobionics.io/press/news/neurobionics-announces-oversubscribed-10m-seed-round-with-second-close-led-by-future-ventures/ ).
The second announcement does not describe an additional standalone USD 10M round. Do not double-count USD 5M plus USD 10M as USD 15M. Neither release discloses Future Ventures' own contribution. Descriptions of preclinical validation and planned first-in-human work are company statements and development plans, not clinical efficacy findings. Future Ventures must not be confused with Future Energy Ventures.
### Neuralink — direct neurotechnology; funding attribution caveat
The official [Future Ventures investments page](https://future.ventures/investments/ ) contains a Neuralink logo linking to [Jurvetson's July 2019 founding-story page](https://www.flickr.com/photos/jurvetson/48309135746/ ) (uploaded 2019-07-17). TechCrunch reports the founders wrote Neuralink's first check. [Dated reporting](https://techcrunch.com/2023/04/12/talking-with-future-ventures-about-its-new-fund-ai-hype-and-siri-sucking/ ) (2023-04-12). **The original check's fund entity/date remain unresolved**; it must not automatically be assigned to the firm founded in 2018.
[Forge's financing history](https://forgeglobal.com/neuralink_ipo/ ) (undated) separately lists Future Ventures among Series B investors dated 2019-05-10, but that commercial database is secondary evidence and its multiple share classes/amounts need primary confirmation. Treat this as a probable firm investment association, not a fully verified round amount. Neuralink's [official Series C announcement](https://neuralink.com/updates/series-c-funding-round-announcement/ ) (2021-07-29) confirms implanted high-channel-count brain-computer-interface technology and USD 205M financing, but **does not name Future Ventures**. Do not attach Future Ventures to that round from logo presence alone.
### Adjacent mental-health investment: Osmind
Osmind's [official USD 40M Series B announcement](https://www.osmind.org/blog/osmind-raises-40-million-series-b-round ) (**2022-05-10**, led by DFJ Growth) explicitly names Future Ventures as an existing investor participating. Its EHR and outcomes-data software supports ketamine, SPRAVATO and transcranial magnetic stimulation practices. This is **neurotech-adjacent psychiatric workflow/research software**, not proof of direct stimulation hardware, neural sensing or a BCI investment. Snapshot `Osmind transv2` should be reviewed as a malformed company name.
The snapshot also lists atai Life Sciences; financing attribution and the appropriate neuroscience-drug-discovery classification were not independently resolved. A general psychiatric/psychedelic drug company should not be silently counted as direct neural-interface technology.
## Conflicts, missing information and later Adex review
1. Add evidence-backed fund history including Fund IV and the AI vehicle; do not leave Fund III as an asserted latest fund. Investigate the Magicus listing through a primary announcement or filing before accepting its manager association.
2. Retain the seed/early-stage mandate, separating it from later historical financing participation. Check sizes, current AUM, fund-level returns, remaining capital and portfolio ownership are not verified.
3. Correct Faeth's lead attribution to co-lead and consolidate duplicate/garbled company records only after exact company identity review. Update undated 64x Bio, Deep Genomics, Mythic, Molten Salt Solutions, Osmind and NeuroBionics claims using the dated financing evidence above.
4. For NeuroBionics, preserve the initial USD 5M seed and second close bringing aggregate funding to USD 10M; indicate Future Ventures leads the second close, not the first. Never attribute these to Future Energy Ventures.
5. Separate partners' DFJ/Khosla/Airbus-era investments and board seats from Future Ventures fund investments. Neither an official portfolio logo nor Signal's historical examples establish original firm/fund attribution. Neuralink's original check and its secondary-reported 2019 round require that review.
6. These examples are a focused verified set, not an exhaustive audit of all 78 snapshot participation records. Unknown transaction dates, fund allocation and checks remain unknown. The omitted logo imports are not findings of no investment.
No MCP Patch, database update, commit or unrelated file change was made for this dossier. SHOW MORE
team@apexlogos.ai · 3 hours ago
Match research 2026-10-06 / FutureVentures / sha256:acaba7cb36a59f9e04e637ba693ac1e1a5357893d00950571a6b9fc5831f33d6 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# Future Ventures
- Exact Adex ID: `FutureVentures`
- Canonical Adex URL: https://adex.page/firms/FutureVentures
- Official website: https://future.ventures/
- Research date: 2026-10-06
- Status: complete research dossier; research only, no Adex/database edits.
Future Ventures is the US frontier-technology venture firm co-founded by Steve Jurvetson and Maryanna Saenko in 2018, distinct from Northwestern Mutual Future Ventures, Baruch Future Ventures and Future\Perfect Ventures. Its official mandate is seed and early-stage investing. Primary sources establish investments in fusion, semiconductor computing, synthetic biology and implantable neuromodulation. The latest numbered flagship fund verified here is **Fund IV: USD 200 million fully sold in a May 2025 SEC filing**, with an additional separately identified 2024 AI vehicle. This is latest-known verified evidence, not an assertion that no newer vehicle exists. [Official firm site](https://future.ventures/ ) (undated), [NFX Signal](https://signal.nfx.com/firms/future-ventures ) (undated), [Fund IV Form D](https://www.sec.gov/Archives/edgar/data/2065683/000206235125000001/xslFormDX01/primary_doc.xml ) (2025-05-06). All external sources below were accessed 2026-10-06.
## Adex and Signal starting evidence
The saved exact-ID snapshot `data/research/_sources/FutureVentures.adex.json`, retrieved 2026-10-06T19:29:39.995Z, contains the 2018 founding date, frontier-technology description, both founders' roles and a Signal URL. Its check minimum, maximum and sweet spot are null. It contains **78 investment participation records**, mostly undated imports of logos/founding stories from the firm's investments page. The two dated baseline transactions are Faeth's USD 20 million seed on 2022-01-18 (lead flag) and Commonwealth Fusion Systems' USD 115 million Series A on 2019-06-27 (participant). Both are corroborated below; Faeth was a **co-lead**, rather than sole lead.
Snapshot data quality issues include separate `Faeth`/`Faeth Therapeutics` and `Commonwealth Fusion Systems`/`CFS-` entries; names containing dates or image artifacts such as `Moonwalk ---2`, `Osmind transv2`, `Prellis Bio 2024-0906-`, `XAI 2024-0513-` and `Vironexis 2024-0903-`; and numerous historical partner investments. These are source-import clues, not verified financing rounds. The official [investments page](https://future.ventures/investments/ ) (undated) identifies a current portfolio and then separately describes logo-linked founding stories, often for investments led by a Future Ventures partner. Its browser text extraction exposed few logos; direct HTML inspection confirmed Neuralink links to Jurvetson's Flickr story and NeuroBionics links to the company site.
[NFX Signal firm profile](https://signal.nfx.com/firms/future-ventures ) was directly read, not merely found in a search index. It supplies the 2018 founding date and broad disruptive-technology interests including space, deep learning, quantum computing, robotics, AI, transportation, synthetic biology and cultivated meat. The profile frames historical successes as the **founders'** investments. Its references to Tesla, SpaceX, Nervana and other early successes cannot establish this firm's original fund attribution. No visible check-size fields or substantive team profiles were returned. Signal and the Adex snapshot are discovery evidence, not independent verification.
## Fund sizes, vintages and status
Amounts are fund capital, not investee rounds or individual check sizes.
| Vehicle | Amount and status | Date/evidence | Caveat |
| --- | --- | --- | --- |
| Fund I | USD 200M; firm says a single close | Official [news page](https://future.ventures/news ), undated launch item; launch independently dated 2019-02-15 by [TechCrunch](https://techcrunch.com/2019/02/15/steve-jurvetson-tells-all-about-his-new-200-million-fund-his-new-partner-his-new-shopping-list-and-more/ ) | The firm's establishment in 2018 differs from the 2019 public fund launch. |
| Fund II / Future Ventures 2 | USD 200M; closed | Official [news page](https://future.ventures/news ), undated; dated 2021-01-12 by [TechCrunch](https://techcrunch.com/2021/01/12/a-deep-dive-on-steve-jurvetson-and-maryanna-saenkos-200-million-new-fund/ ) | A separate vintage, not AUM. |
| Fund III | USD 200M; closed | Official [news page](https://future.ventures/news ), undated; April 2023 dated coverage: [TechCrunch](https://techcrunch.com/2023/04/12/talking-with-future-ventures-about-its-new-fund-ai-hype-and-siri-sucking/ ) (2023-04-12) | Do not confuse flagship III with separately named Final Frontier Fund III. |
| Future Ventures AI, LLC | USD **168,873,585** offering and amount sold, USD 0 remaining; 68 investors | [SEC Form D](https://www.sec.gov/Archives/edgar/data/2021509/000202150924000001/xslFormDX01/primary_doc.xml ), signed 2024-05-30; first sale 2024-05-09 | Separate vehicle managed by Future Ventures GP III, LLC; filing does not establish a broad new flagship mandate. Rounded USD 169M reports are consistent with the exact filing figure. |
| Future Ventures IV, L.P. | USD **200,000,000** offering and amount sold, USD 0 remaining; 123 investors | [SEC Form D](https://www.sec.gov/Archives/edgar/data/2065683/000206235125000001/xslFormDX01/primary_doc.xml ), signed/filed 2025-05-06; first sale 2025-05-02; [filing index](https://www.sec.gov/Archives/edgar/data/2065683/0002062351-25-000001-index.htm ) | Fully sold offering as disclosed by issuer; SEC filing is not an SEC audit of accuracy. |
The [Final Frontier Fund III SEC filing](https://www.sec.gov/Archives/edgar/data/1930168/000193016822000002/xslFormDX08/primary_doc.xml ) (2022-06-03) confirms another similarly numbered vehicle exists. It is not treated as flagship Fund III or combined with the amounts above.
No current independently verified AUM or unallocated investment budget was established. Do not simply add historical fund commitments and call the result current AUM: side funds, SPVs, overlapping vehicles, distributions and valuations can affect that number. Searches for Fund V and 2026 closes found no primary-source-confirmed newer flagship. [Private Equity International's profile](https://www.privateequityinternational.com/institution-profiles/future-ventures.html ) (undated) lists “Magicus Ventures,” September 2026, under this manager, but conceals size and also contains generic placeholder language. **This is an unresolved potentially misassigned lead**, not a verified new Future Ventures fund.
## Investment stages
The [official homepage](https://future.ventures/ ) (undated) explicitly states **seed and early-stage** investing. Verified transactions span seed (Faeth, NeuroBionics and Molten Salt Solutions), Series A (Commonwealth Fusion Systems and 64x Bio) and Series B (Deep Genomics). These historical financing stages do not establish an unrestricted later-stage new-investment mandate. Mythic's 2025 financing also confirms ongoing participation beyond original seed investments. No current primary-source check-size range was verified; retain Adex's unknown fields unless separately substantiated.
## Named deep-tech investments verified
All amounts below are **total company rounds**, not amounts contributed by Future Ventures. Technology labels are research classifications grounded in the cited product descriptions; no performance claims have been independently tested.
| Company | Technology rationale | Firm attribution, round/date and source |
| --- | --- | --- |
| **Commonwealth Fusion Systems** | Nuclear fusion hardware and high-temperature superconducting magnets for compact fusion systems | New participant in closed **USD 115M Series A**, **2019-06-27**. Company release explicitly names Future Ventures and quotes Jurvetson in that capacity. [Official release](https://cfs.energy/news-and-media/close-series-a-round/ ). Historical projected SPARC milestones in that release are not evidence of later achievement. |
| **Deep Genomics** | Proprietary AI platform to discover and develop genetic-disease therapeutics; combines computational and biological R&D | **Led closed USD 40M Series B**, **2020-01-07**. [Official release](https://www.deepgenomics.com/news/deep-genomics-raises-40-million-in-series-b-financing ). Classification is biotech/computational drug discovery, not direct neurotechnology. | SHOW MORE
team@apexlogos.ai · 22 days ago
MATCH 
Khosla Ventures
Faeth$20M · 2022-01-18
Commonwealth Fusion Systems$115M · 2019-06-27
Candace Richardson
Osmind$40M · 2022-05-10
Dolby Family Ventures
Molten Salt Solutions$7M · 2026-08-31
Fifty Years
64xBio$55M · 2022-01-19
Future Fund
Katherine Boyle
Rouz Jazayeri
Mythic$125M · 2025-12-17
Vinod Khosla
Deep Genomics$40M · 2020-01-07
